Surotomycin
Surotomycin was an investigational oral antibiotic. This antibiotic was under investigation by Merck & Co (who acquired Cubist Pharmaceuticals) for the treatment of life-threatening Diarrhea, commonly caused by the bacterium Clostridium difficile. Reference standards of Surotomycin API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
stdClass Object
(
[pname] => Surotomycin - API Standards
[catalogue_number] => PA 19 1630000
[category_ids] => ,75,76,78,70,82,
[chemical_name] =>
[weight] => 1680.75
[form] => C77H101N17O26
[cas] => 1233389-51-9
[pslug] => 1233389-51-9-surotomycin-api-pa191630000
[latest_product] => 0
[linkproducts] => 0
[offers_id] =>
[offers_name] =>
[offers_status] =>
[offers_start_date] =>
[offers_end_date] =>
[pageview] =>
[offers_slug] =>
[offers_product_id] =>
[offers_product_code] =>
[offers_master_id] =>
[offer_percentage] =>
[offers_product_main_cat] =>
)
Surotomycin - API Standards
Catalogue No.:PA 19 1630000
Molecular Formula : C77H101N17O26
Molecular Weight : 1680.75